Formulation Brief & Sample Request Guide for Cleanser

Key Technical Parameters #

Getting a cleanser from concept to sample is where most brand projects either move fast or stall completely. The stall almost always happens at the same point: the brief. When brand partners come to us without a structured brief, we spend the first two weeks asking questions we should have had answered on day one — and that delay compounds through every downstream step. This guide covers the complete intake process we run with new brand partners, from brief structure through sample evaluation to production handoff, written for founders who know what they want to launch but haven’t navigated OEM development before.

The Brief That Actually Gets You What You Want #

A vague brief is the most expensive document in product development. We see it constantly — a one-paragraph email that says “we want a gentle foaming cleanser, natural, good for sensitive skin, no parabens.” That tells us almost nothing we can act on.

When a brand partner briefs us on a new cleanser, the first questions we ask are: What market is this launching in? What’s the on-pack claim story? What does your target consumer’s bathroom shelf already look like?

Those three questions change the formulation direction entirely. A foaming cleanser for the EU market requires compliance with EU Cosmetics Regulation 1223/2009, which restricts certain preservatives and surfactants that are still routinely used in US-market products. A “natural” claim in Germany carries different connotations than it does in the US, and our formulation approach shifts accordingly. If you haven’t locked your market before briefing us, we’ll ask you to do that first.

The brief elements we actually need, ranked by how much ambiguity costs time:

1. Target claims and positioning. Not just “gentle” — do you want a clinical mildness claim backed by a TEWL study? A microbiome-safe claim? A makeup removal efficacy figure? Each claim triggers a different test protocol and adds 3–6 weeks to your timeline. Be specific about what’s going on-pack and what’s only in marketing copy.

2. Texture and sensory target. This is where brands consistently underestimate the detail required. “Rich lather” means different things to a Korean consumer and a French consumer. If you have a benchmark product — a competitor SKU or a consumer-favorite cleanser — send it to us. Physically. We evaluate it in the lab, reverse-engineer the sensory profile, and use it as an anchor for your formulation direction. Benchmark products cut development cycles by roughly 30% in our experience.

3. Ingredient inclusions and exclusions. If you’re building a clean beauty brand with a published “no” list, send that list in the brief. We run it through what we internally call the FR-01 ingredient screen before we touch the formulation. Every ingredient on your exclusion list that shows up in a standard cleanser base needs a replacement, and each substitution has a performance cost we need to plan around. Sodium lauryl sulfate (SLS) is the obvious example — brands that ban it often don’t realize they’re also excluding the most cost-effective high-foam option, and the alternatives at equivalent foam performance typically add $0.08–0.15 per unit at production scale.

4. Packaging concept. Not finalized art — we just need the closure type, tube or bottle format, and whether it’s opaque or transparent. Formulas that look fine in our white HDPE development bottles sometimes look completely different in amber PET. We’ve had batches where a perfectly stable formula turned slightly yellow in a transparent tube under warehouse lighting conditions — not a safety issue, but a visual quality issue that required formula adjustment. Knowing the pack format early prevents that kind of late-stage rework.

5. Target price point. This is the one brands most often skip, treating it as a negotiation card. In practice, your cost target determines whether we start with a premium surfactant blend or a standard one, whether encapsulated actives are viable, and how complex the fragrance brief can be. Tell us. We’re not using it against you — we’re using it to build you something that actually fits your business.

From Brief Approval to Lab Sample: What Happens and How Long It Takes #

Once we have a complete brief — and we mean complete, not “good enough” — the development timeline runs as follows.

Initial formulation work takes 2–3 weeks. That covers selecting the base system, building the first prototype internally, running basic bench stability at 40°C/75% RH, and evaluating it against your benchmark if one was provided. We typically produce 3–5 internal variants before selecting 1–2 to send to you, because sending you five samples with no differentiation just creates confusion on your end. We’d rather show you “here’s the high-foam option and here’s the gentler option with lower surfactant load” — two clear choices that map to a real decision.

Lab sample quantities run at 100–200g per variant as standard. MOQ for samples is not the same as MOQ for production. Sample production happens at bench scale in our R&D lab, so there’s no minimum batch size constraint. Production MOQ is a different conversation — typically 500kg per batch for tube formats, 300kg for bottle formats, though this varies by formula complexity.

After you receive samples, we give you a 2-week evaluation window before we follow up. Most of the brands we work with are running their samples through internal team evaluation, consumer panels, or comparison against competitors. The evaluation criteria we recommend:

• Sensory: foam quality (volume, bubble size), rinse-feel (squeaky vs. comfortable), post-wash skin feel at 15 minutes and 60 minutes
• Visual: clarity, color consistency batch-to-batch, any phase separation or cloudiness
• Efficacy proxy: if makeup removal is a claim, test against your standard makeup products on your own skin — you know your benchmark better than we do
• Fragrance retention: cleansers are rinse-off, so top notes dominate; check whether the scent profile reads correctly to your brief

Accelerated stability runs 4–8 weeks at 40°C (per ICH Stability Guidelines), and we initiate real-time 24-month stability concurrently from the first approved prototype batch. Don’t wait for accelerated data before initiating real-time — that’s a timeline mistake that costs you months.

The complete cycle from brief to sample approval typically runs 8–12 weeks for a standard cleanser. Add 3–6 weeks if you need a specific efficacy study. Add another 4 weeks if the formula requires significant reformulation after your first review.

The Parameters That Separate a Development Fee from a Unit Cost #

Cost structure in OEM cleanser development has two distinct components, and conflating them is a common source of friction.

Development fees cover R&D labor, raw material costs for prototype batches, and initial stability testing. These are typically charged at project initiation and are non-refundable. For a standard cleanser with no unusual active requirements, development fees run in the range of $800–$2,500 depending on complexity. Multi-variant development (three or more distinct formulas in parallel) carries a higher fee. Brands that arrive with a complete brief and a benchmark product pay less — the work is faster.

Per-unit production costs are what you see in your final COGS once the formula is approved and you’re in production. These are quoted against your confirmed MOQ and packaging specification. The development fee does not roll into the per-unit cost — they’re separate line items.

The most common misunderstanding we encounter: brands assume that paying a development fee means subsequent revisions are free. Revisions after formula approval that require new raw materials, new stability runs, or new efficacy testing are billed separately. Minor adjustments — fragrance concentration tweaks, color correction, viscosity adjustment within the original system — are generally covered. The line between “adjustment” and “reformulation” is something we walk through with brand partners during the brief stage, because ambiguity there leads to invoice disputes later.

One cost driver that surprises new brand partners is the stability re-run fee. If you change your packaging after formula approval — even just the closure type — we may need to re-run packaging compatibility testing. This costs time more than money, but for a launch-critical timeline, it’s a real risk. Lock your packaging before formula approval. Not after.

On the efficacy data question: if your cleanser makes a clinical skin-feel or mildness claim, you’ll need substantiation data. A 2022 split-face clinical study (n=44, 8 weeks, daily use twice daily) on a surfactant-optimized mild cleanser system showed a 22% reduction in TEWL versus a standard SLS-based benchmark, with statistically significant improvement in self-reported skin tightness scores by week 4. That’s the type of data that supports a “clinically shown to be gentle” on-pack claim. PCPC Guidelines provide useful direction on what level of substantiation is expected for cosmetic efficacy claims in the US market.

Decision Framework: Which Path to Take Based on Your Situation #

If you have a clear benchmark product and a defined market, start with a brief that includes the benchmark physical sample and a one-page claims document. We can turn around initial prototypes in 2 weeks from that starting point.

If your brief is concept-only — you know the positioning but haven’t finalized claims, packaging, or price point — expect a 2-week pre-formulation alignment phase before lab work starts. That’s not wasted time. Going into formulation without resolving those variables means reformulation later, which costs more.

If you’re developing for multiple markets simultaneously — EU and US at minimum — tell us upfront. The formula may be identical but the documentation, labeling, and compliance review diverge. FDA Cosmetics Guidelines and EU Cosmetics Regulation have different requirements for rinse-off product registration, ingredient nomenclature, and claim substantiation. Running parallel compliance tracks from day one is far less painful than adapting a US-approved formula for EU post-launch.

Our acid-exfoliation-technology page covers the additional qualification steps required when AHA or BHA actives are included in a cleanser formula — the pH window, contact time considerations, and the difference in regulatory treatment between EU and US markets for exfoliating claims. Worth reviewing if that’s part of your brief.

If your launch timeline is under 6 months from today and you don’t yet have a brief, be honest with yourself about that timeline. A standard cleanser development cycle runs 8–12 weeks to sample approval, plus 4–6 weeks for production scheduling and filling. That’s 12–18 weeks minimum before product is in your hands. We can compress some steps, but not all of them.

For brands requesting our cleanser formulation portfolio specifically: if you’re building on an existing base formula and customizing rather than developing from scratch, the timeline shortens to 4–6 weeks and the development fee is typically 40–50% lower. This path works well for brands that want a proven, stability-verified base and are primarily differentiating through fragrance, actives, color, and claims. It’s not the right approach if your differentiation is the formula itself.

Formulation Notes for Brand Partners #

When you brief us on a cleanser, the first things we need to know are your target market, your on-pack claim priority, and what format you’re working in. Those three variables determine everything downstream — base system, pH range, preservative choice, and test protocol.

The most common brief mistake we see from new brand partners is leading with aesthetics and leaving claims undefined. A brand will spend two weeks perfecting the fragrance brief and submit it alongside a texture mood board, but not specify whether they need a mildness claim or a makeup removal claim. Those claims require different formulation approaches and different test protocols. We almost always push back and ask the claims question before we start bench work. It saves a reformulation round later.

A realistic timeline: once we have a complete brief, lab samples take 2–3 weeks. Accelerated stability runs 4–8 weeks. We initiate 24-month real-time stability concurrently from the first approved prototype batch. After sample approval, production scheduling adds 4–6 weeks for standard orders. Bespoke packaging or custom components add time — sometimes significantly. If your launch date is fixed, work backward from it and brief us earlier than you think you need to.

One specific scenario we see often: brands finalize packaging after formula approval and then discover the closure type or tube material requires compatibility re-testing. Build packaging finalization into your brief timeline, not after it.

Frequently Asked Questions #

We want to send you a benchmark product to match — does that actually work?
A: It works well for texture and sensory profile, but benchmark matching has limits. We can get very close on foam character, rinse-feel, and viscosity. We can’t replicate a proprietary fragrance, and if the benchmark uses an ingredient on your exclusion list, we’ll need to find a functional substitute that changes the sensory outcome somewhat. Send the benchmark anyway — it’s still the fastest way to align on direction.

Can we include AHA in the cleanser and still claim it’s gentle?
A: It depends on concentration and pH. At 2% glycolic acid and pH 4.0–4.5, you’re in exfoliant territory under EU Cosmetics Regulation 1223/2009 and need specific on-pack warnings. At 0.5–1.0% and pH 5.0–5.5, the exfoliant effect is minimal and most markets treat it as a conditioning ingredient. The claim you want to make on-pack needs to match the concentration and pH you’re actually using — we’ve had brands ask for both “gentle” and “exfoliating” on the same formula, and that combination triggers a compliance conversation in most markets.

What happens if the first samples aren’t quite right — how many rounds do we get?
A: One revision round is standard within the development fee for minor adjustments. If the issue is fragrance alignment or a small viscosity correction, that’s covered. If the first batch reveals a fundamental mismatch between the brief and what we made — which usually means the brief was incomplete — a second full revision may carry an additional fee. We flag this risk during brief review so it doesn’t come as a surprise. We’ve had projects where three revision rounds were needed; that’s more about an evolving brief than a formulation problem.

What’s the actual MOQ to get into production once the formula is approved?
A: For tube-format cleansers, production MOQ is typically 500kg per batch, which translates to roughly 10,000 units at 50g fill or 5,000 units at 100g fill. Bottle formats can run at 300kg in some cases. If your launch volume is smaller than that, we can discuss base-formula licensing or a staggered production arrangement, but those conversations happen after formula approval and pricing alignment.

We’re planning to launch in the EU and the US at the same time — do we need two separate formulas?
A: Often no, but not always. The formula itself may be identical across both markets. What differs is documentation, labeling structure, and sometimes preservative choice — certain preservatives permitted under FDA Cosmetics Guidelines are restricted under EU regulation. The honest answer on whether you need one formula or two depends on your specific ingredient list. We run a parallel compliance screen across both markets as part of our standard brief intake for international launches, which surfaces any conflicts before we start formulation rather than after.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.